FY2026 Earnings Forecast for CMPX Issued By HC Wainwright

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Compass Therapeutics in a research note issued to investors on Thursday, March 5th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.40) per share for the year, up from their prior estimate of ($0.57). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ FY2028 earnings at ($0.52) EPS.

A number of other research analysts have also recently commented on CMPX. Leerink Partners upgraded shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Cantor Fitzgerald started coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “overweight” rating on the stock. Raymond James Financial reaffirmed an “outperform” rating on shares of Compass Therapeutics in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a research note on Thursday. Finally, Canaccord Genuity Group set a $13.00 price objective on Compass Therapeutics in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Compass Therapeutics Stock Down 1.6%

Shares of Compass Therapeutics stock opened at $5.42 on Monday. The stock’s fifty day moving average is $5.90 and its two-hundred day moving average is $4.84. Compass Therapeutics has a 52 week low of $1.33 and a 52 week high of $6.88. The company has a market capitalization of $976.09 million, a PE ratio of -12.60 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new position in Compass Therapeutics in the fourth quarter worth about $132,000. Seven Fleet Capital Management LP bought a new stake in shares of Compass Therapeutics in the 4th quarter valued at about $3,054,000. Invesco Ltd. boosted its holdings in shares of Compass Therapeutics by 5.3% in the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares in the last quarter. XTX Topco Ltd grew its position in shares of Compass Therapeutics by 582.2% in the 4th quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock worth $621,000 after buying an additional 98,684 shares during the last quarter. Finally, Ikarian Capital LLC bought a new position in shares of Compass Therapeutics during the 4th quarter worth approximately $4,296,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.